Matches in UGent Biblio for { <https://biblio.ugent.be/publication/2979795#aggregation> ?p ?o. }
Showing items 1 to 92 of
92
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B617823.
- aggregation creator B617824.
- aggregation creator B617825.
- aggregation creator B617826.
- aggregation creator B617827.
- aggregation creator B617828.
- aggregation creator B617829.
- aggregation creator B617830.
- aggregation creator B617831.
- aggregation creator B617832.
- aggregation creator B617833.
- aggregation creator B617834.
- aggregation creator B617835.
- aggregation creator B617836.
- aggregation creator B617837.
- aggregation creator B617838.
- aggregation creator B617839.
- aggregation creator B617840.
- aggregation creator B617841.
- aggregation creator B617842.
- aggregation creator B617843.
- aggregation creator B617844.
- aggregation creator B617845.
- aggregation creator B617846.
- aggregation creator B617847.
- aggregation creator B617848.
- aggregation creator B617849.
- aggregation creator B617850.
- aggregation creator B617851.
- aggregation creator B617852.
- aggregation creator B617853.
- aggregation creator B617854.
- aggregation creator B617855.
- aggregation creator B617856.
- aggregation creator B617857.
- aggregation creator B617858.
- aggregation creator B617859.
- aggregation creator B617860.
- aggregation creator B617861.
- aggregation creator B617862.
- aggregation creator B617863.
- aggregation creator B617864.
- aggregation creator B617865.
- aggregation creator B617866.
- aggregation creator B617867.
- aggregation creator B617868.
- aggregation creator B617869.
- aggregation creator B617870.
- aggregation creator B617871.
- aggregation creator B617872.
- aggregation creator B617873.
- aggregation creator B617874.
- aggregation creator B617875.
- aggregation creator B617876.
- aggregation creator B617877.
- aggregation creator B617878.
- aggregation creator B617879.
- aggregation creator B617880.
- aggregation creator B617881.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2012".
- aggregation format "application/pdf".
- aggregation hasFormat 2979795.bibtex.
- aggregation hasFormat 2979795.csv.
- aggregation hasFormat 2979795.dc.
- aggregation hasFormat 2979795.didl.
- aggregation hasFormat 2979795.doc.
- aggregation hasFormat 2979795.json.
- aggregation hasFormat 2979795.mets.
- aggregation hasFormat 2979795.mods.
- aggregation hasFormat 2979795.rdf.
- aggregation hasFormat 2979795.ris.
- aggregation hasFormat 2979795.txt.
- aggregation hasFormat 2979795.xls.
- aggregation hasFormat 2979795.yaml.
- aggregation isPartOf urn:issn:1058-4838.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Maternal HIV-1 disease progression 18-24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): the Kesho Bora randomized controlled trial".
- aggregation abstract "Background. Antiretroviral (ARV) prophylaxis effectively reduces mother-to-child transmission of human immunodeficiency virus type 1 (HIV). However, it is unclear whether stopping ARVs after breastfeeding cessation affects maternal HIV disease progression. We assessed 18-24-month postpartum disease progression risk among women in a randomized trial assessing efficacy and safety of prophylactic maternal ARVs. Methods. From 2005 to 2008, HIV-infected pregnant women with CD4(+) counts of 200-500/mm(3) were randomized to receive either triple ARV (zidovudine, lamivudine, and lopinavir/ritonavir during pregnancy and breastfeeding) or AZT/sdNVP (zidovudine until delivery with single-dose nevirapine without postpartum prophylaxis). Maternal disease progression was defined as the combined endpoint of death, World Health Organization clinical stage 4 disease, or CD4(+) counts of <200/mm(3). Results. Among 824 randomized women, 789 had at least 1 study visit after cessation of ARV prophylaxis. Following delivery, progression risk up to 24 months postpartum in the triple ARV arm was significantly lower than in the AZT/sdNVP arm (15.7% vs 28.3%; P = .001), but the risks of progression after cessation of ARV prophylaxis (rather than after delivery) were not different (15.0% vs 13.8% 18 months after ARV cessation). Among women with CD4(+) counts of 200-349/mm(3) at enrollment, 24.0% (95% confidence interval [CI], 15.7-35.5) progressed with triple ARV, and 23.0% (95% CI, 17.8-29.5) progressed with AZT/sdNVP, whereas few women in either arm (<5%) with initial CD4(+) counts of >= 350/mm(3) progressed. Conclusions. Interrupting prolonged triple ARV prophylaxis had no effect on HIV progression following cessation (compared with AZT/sdNVP). However, women on triple ARV prophylaxis had lower progression risk during the time on triple ARV. Given the high rate of progression among women with CD4(+) cells of <350/mm(3), ARVs should not be discontinued in this group.".
- aggregation authorList BK977659.
- aggregation endPage "460".
- aggregation issue "3".
- aggregation startPage "449".
- aggregation volume "55".
- aggregation aggregates 2980014.
- aggregation isDescribedBy 2979795.
- aggregation similarTo cis461.
- aggregation similarTo LU-2979795.